Solvotrin Therapeutics is a pharmaceutical company that focuses on improving and enhancing existing medications. Founded by Pat O’Flynn in 2009, Solvotrin Therapeutics is backed by investors that include Enterprise Ireland, Elkstone Capital Partners, Elkstone, RAB Capital, and Kevin Fielding and is headquartered in Cork.